Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Amneal Pharmaceuticals

- PMLiVE

Mission Therapeutics advances Parkinson’s disease candidate

The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

- PMLiVE

PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

The US-based company develops light-based therapies for neurodegenerative conditions

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

- PMLiVE

FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

The mosquito-borne viral disease has been reported across many popular travel destinations

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

- PMLiVE

FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM

Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

The serious adverse event reported was found to be unrelated to the vaccine

- PMLiVE

FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia

Approximately 8,400 adults are diagnosed with the aggressive blood cancer every year in the US and EU

- PMLiVE

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea

The long-term skin condition affects more than 16 million people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links